8 Sources of evidence considered by the Committee

8 Sources of evidence considered by the Committee

A. The Evidence Review Group (ERG) report for this appraisal was prepared by Liverpool Reviews and Implementation Group:

  • Fleeman N, Bagust A, Boland A et al., Nintedanib for previously treated locally advanced or metastatic non‑small‑cell lung cancer, October 2014

B. The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, the ERG report and the appraisal consultation document (ACD). Organisations listed in I were also invited to make written submissions. Organisations listed in II and III had the opportunity to make written submissions. Organisations listed in I, II and III also have the opportunity to appeal against the final appraisal determination.

I. Company:

  • Boehringer Ingelheim

II. Professional/expert and patient/carer groups:

  • Roy Castle Lung Cancer Foundation

  • British Thoracic Oncology Group

  • British Thoracic Society

  • Cancer Research UK

  • Royal College of Pathologists

  • Royal College of Physicians

III. Commentator organisations (did not provide written evidence and without the right of appeal):

  • Roche Products

  • National Collaborating Centre for Cancer

C. The following individuals were selected from clinical expert and patient expert nominations from the consultees and commentators. They gave their expert personal view on nintedanib by attending the initial Committee discussion and providing a written statement to the Committee. They were also invited to comment on the appraisal consultation document.

  • Dr Thomas Newsom‑Davis, Consultant Medical Oncologist, Chelsea & Westminster Hospital, nominated by NCRI/RCP/RCR/ACP – clinical expert

  • Dr Jesme Fox, Medical Director, Roy Castle Lung Cancer Foundation, nominated by Roy Castle Lung Cancer Foundation – patient expert

D. Representatives from the following company attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

  • Boehringer Ingelheim

  • National Institute for Health and Care Excellence (NICE)